Jennifer M. Gascoyne

Latham & Watkins advised Cian PLC, a leading online real estate classifieds platform in Russia, on the pricing of its initial public offering of 18,213,400 American Depositary Shares (ADSs), each representing one ordinary share of Cian, 4,042,400 of which are being offered by Cian and 14,171,000 of which are being offered by certain selling shareholders of Cian (Selling Shareholders), at a price to the public of US$16 per ADS. The Selling Shareholders have also granted the underwriters of the IPO a 30-day option to purchase up to an additional 2,732,010 ADSs, at the initial public offering price, less underwriting discounts and commissions. The ADSs are expected to begin trading on the New York Stock Exchange and the Moscow Exchange on November 5, 2021 under the symbol “CIAN”. The Latham team was led by corporate partners David Stewart and Olga Ponomarenko, with associates Daria Latysheva, Jennifer Gascoyne, Matthew Fisher, Viktoria Petukhova, Laura Harper, Alexander Fedorkov, Nina Malkova, and Anton Vologin. Advice on benefits matters was provided by partner Jennifer Pepin; and on tax matters by partner Jiyeon Lee-Lim and associate Lauren Bewley.~~

Nov 5

1 min

atai Life Sciences B.V., a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, has announced the pricing of its upsized initial public offering in the United States of 15,000,000 common shares at a price to the public of US$15 per share. All common shares are being offered by atai. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by atai, are expected to be US$225 million. In addition, atai has granted the underwriters a 30-day option to purchase up to an additional 2,250,000 common shares at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on June 22, 2021, subject to customary closing conditions. atai’s common shares are expected to begin trading on the Nasdaq Global Market on June 18, 2021 under the ticker symbol “ATAI.” Latham & Watkins LLP represents atai Life Sciences in the offering with a capital markets team led by New York partners Nathan Ajiashvili and Ian Schuman and Frankfurt partner Oliver Seiler, with associates Jennifer Gascoyne, Victoria McGrath, Ryan Hudson, and Hamna Ahmad.~~

Jun 21

1 min

Farfetch Limited, the leading global technology platform for the luxury fashion industry listed on the NYSE, announced today that it has entered into binding agreements with the current shareholders of New Guards Group S.p.A., a platform for luxury brands’ design, productions, and distribution, to acquire, through its subsidiary Farfetch Italia S.r.l., the entire share capital of New Guards Group S.p.A., whose total enterprise value has been valued at US$675,000,000. The consideration payable by Farfetch Italia S.r.l. will be split equally between cash and shares of Farfetch Limited. The acquisition of New Guards Group S.p.A. by the Farfetch group supports Farfetch’s strategy as the global technology platform for luxury fashion, empowering individuality and connecting creators, curators, and customers. Latham & Watkins represents Farfetch Limited and its subsidiary Farfetch Italia S.rl. in the transaction, with a cross-border team led from Milan by corporate partner Stefano Sciolla, with associates Giovanni Spedicato, Silvia Milanese, and Chiara Venditti. Advice was also provided on finance matters by Milan partner Marcello Bragliani with associate Erika Brini Raimondi; on regulatory matters by Milan counsel Cesare Milani with associate Virginia List; on English law matters by London partner Edward Barnett with associates Samantha Peacock, Drishi Beeharry, Hendrik Smit, and Haya Aftab; and on US law matters by London partner Joshua Kiernan, New York partners Ian Schuman and Adam Gelardi, and London associate Jennifer Gascoyne.~~

Aug 9

1 min

Latham & Watkins has advised Abcam plc (Nasdaq: ABCM), a global leader in the supply of life science research tools, on a definitive agreement pursuant to which Danaher Corporation (NYSE: DHR) will acquire all of the outstanding shares of Abcam for US$24 per share in cash (the ‘Transaction’), with a total enterprise value of approximately US$5.7 billion including assumed indebtedness and net of acquired cash. The Transaction has been unanimously approved and recommended by the Abcam Board of Directors and unanimously approved by the Danaher Board of Directors. Latham has previously advised Abcam on its listing on NASDAQ, de-listing from AIM, strategic M&A activities, and a recent activist campaign. The Latham team was led by London corporate partners Robbie McLaren, Richard Butterwick, Anna Ngo, and Jennifer Gascoyne, with associates Chris Ramsey, Aimee Godfrey, Aeneas Nalbantis, and Will Temple-Smith. Advice on US corporate matters was provided by Orange County partner Scott Shean and New York partner Leah Sauter; on executive compensation, employment & benefits matters by London partner Sarah Gadd and Washington, D.C. partner Nikhil Kumar; and on antitrust and regulatory matters by Brussels partner Héctor Armengod and counsel Philipp Studt, and Washington, D.C. partner Mandy Reeves.~~

Aug 28

1 min

Abcam plc (Abcam), a global leader in the supply of life science research tools, has announced the pricing of its offering of 8,945,218 American Depositary Shares (ADSs), representing an aggregate of 8,945,218 ordinary shares, at a price of US$17.50 per ADS, for aggregate proceeds of approximately US$156.5 million, before deducting underwriting discounts and commissions. Each ADS offered represents one ordinary share of Abcam. In addition, Abcam has granted the underwriters a 30-day option to purchase up to an additional 1,341,782 ADSs on the same terms and conditions. Abcam's ordinary shares are admitted to trading on the AIM market of the London Stock Exchange under the symbol "ABC." Abcam’s ADSs are expected to begin trading on Nasdaq on October 22, 2020 under the ticker symbol “ABCM.” The closing of the offering is expected to occur on October 26, 2020, subject to customary closing conditions. Latham & Watkins LLP represented Abcam in the offering with a capital markets team led by New York partners Ian Schuman and Nathan Ajiashvili and London partner Robbie McLaren, with London associates Jennifer Gascoyne, Anna Ngo, Sarah Youssefi, Jackie Yonover, and Frederick Gardner.~~

Oct 22

1 min